Evaluation of osteoporosis risk assessment in veterans receiving androgen-deprivation therapy.
To identify whether veterans receiving androgen-deprivation therapy (ADT) are screened at any time by bone mass measurement. Cross-sectional study. Veterans Administration Tennessee Valley Healthcare System (VA-TVHS). All male veterans who received at least one dose of goserelin or leuprolide within the fiscal years October 1, 2005, through September 30, 2009. Data from patients' charts were extracted for demographic information (race, age, and weight prior to the initial injection); date of initiation of therapy; the use of calcium, vitamin D, bisphosphonate, or calcitonin therapy; and documented bone-mineral density testing. To determine whether veterans receiving ADT with goserelin or leuprolide for prostate cancer were screened at any time for BMD more or less than rates as documented in previous literature. 22.8% of veterans were screened for BMD, which was statistically significant when compared with results found in previous literature. Although rates of BMD testing were higher at VA-TVHS compared with previous literature, this rate is still low given the well-known risk of accelerated osteoporosis associated with ADT.